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Neurobiology of Disease
Toll-Like Receptors and Dectin-1, a C-Type Lectin Receptor,
Trigger Divergent Functions in CNSMacrophages
John C. Gensel,1* YanWang,2* Zhen Guan,2 Kyle A. Beckwith,2 Kaitlyn J. Braun,1 PingWei,2DanaM. McTigue,2
and Phillip G. Popovich2
1Spinal Cord and Brain Injury Research Center, Department of Physiology, University of Kentucky, Lexington, Kentucky 40536, and 2Center for Brain and
Spinal Cord Repair, Department of Neuroscience, Wexner Medical Center at The Ohio State University, Columbus, Ohio 43210
Spinal cord injury (SCI) activates macrophages, endowing them with both reparative and pathological functions. The mechanisms
responsible for these divergent functions are unknown but are likely controlled through stochastic activation of different macrophage
receptor subtypes. Various danger-associated molecular patterns released from dying cells in the injured spinal cord likely activate
distinct subtypes of macrophage pattern recognition receptors, including bacterial toll-like receptors (TLRs) and fungal C-type lectin
receptors (e.g., dectin-1). To determine the in vivo consequences of activating these receptors, ligands specific for TLR2 or dectin-1 were
microinjected, alone or in combination, into intact spinal cord. Both ligands elicit a florid macrophage reaction; however, only dectin-1
activation causes macrophage-mediated demyelination and axonal injury. Coactivating TLR2 reduced the injurious effects of dectin-1
activation. When injected into traumatically injured spinal cord, TLR2 agonists enhance the endogenous macrophage reaction while
conferring neuroprotection. Indeed, dieback of axons was reduced, leading to smaller lesion volumes at the peak of the macrophage
response.Moreover, the density ofNG2 cells expressing vimentin increased in andnear lesions thatwere enrichedwithTLR2-activated
macrophages. In dectin-1-nullmutant (knock-out)mice, dieback of corticospinal tract axons also is reduced after SCI. Collectively, these
data support the hypothesis that the ability of macrophages to create an axon growth-permissive microenvironment or cause neurotox-
icity is receptor dependent and it may be possible to exploit this functional dichotomy to enhance CNS repair.
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Introduction
Spinal cord injury (SCI) elicits a neuroinflammatory reaction
dominated by microglia and monocyte-derived macrophages.
Together, these CNSmacrophages work to restore tissue homeo-
stasis; however, in doing so they also cause additional injury to
neurons and glia. The mechanisms responsible for these diver-
gent effects are not known but likely involve stochastic activation
of different innate immune receptors.
Pattern-recognition receptors (PRRs) detect molecular se-
quences that were first discovered on bacteria and viruses (Bi-
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Significance Statement
There is a growing appreciation that macrophages exert diverse functions in the injured and diseased CNS. Indeed, both
macrophage-mediated repair and macrophage-mediated injury occur, and often these effector functions are elicited simultane-
ously. Understanding the mechanisms governing the reparative and pathological properties of activated macrophages is at the
forefront of neuroscience research. In this report, using in vitro and in vivomodels of relevance to traumatic spinal cord injury
(SCI), new data indicate that stochastic activation of toll-like and c-type lectin receptors onmacrophages causes neuroprotection
or neurotoxicity, respectively. Although this manuscript focuses on SCI, these two innate immune receptor subtypes are also
involved in developmental processes and become activated in macrophages that respond to various neurological diseases.
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anchi, 2007). Emerging data indicate that similar molecular
sequences are released from injured or dying mammalian cells
and both microglia and macrophages recognize these as
“damage-associated molecular patterns” or DAMPs. Common
DAMPs include heat-shock proteins, high-mobility group box 1
protein, and mRNA, and each activates a range of PRRs, includ-
ing toll-like receptors (TLRs) andC-type lectin receptors (CLRs).
In the CNS, activation of microglia or macrophage PRRs can
cause gliogenesis or regeneration of injured axons; however, such
reparative effects are often accompanied by secondary demyeli-
nation and neurotoxicity (Kigerl et al., 2007; Schonberg et al.,
2007;Gensel et al., 2009; Kigerl andPopovich, 2009; Stirling et al.,
2014). These divergent effects could be explained by convergent
signaling elicited by individual DAMPs acting on discrete PRRs
or by the unique effects of distinct DAMP–PRR interactions.
Insight into the functional consequences of activating macro-
phages via multiple PRRs can be gained from experiments using
zymosan, a glucan polysaccharide found on yeast.
Zymosan binds to both TLR2 and dectin-1, a CLR (Lien et al.,
1999; Gantner et al., 2003; Brown, 2006). When injected into
brain or spinal cord, zymosan elicits macrophage-mediated kill-
ing of neurons while also creating a microenvironment that sup-
ports axon regeneration (Fitch et al., 1999; Yin et al., 2003, 2006,
2009;Okada et al., 2005; Steinmetz et al., 2005; Gensel et al., 2009;
Benowitz and Popovich, 2011). In this manuscript, new data
show that the neurotoxic effects of zymosan-activated macro-
phages (ZAMs) are due to CLR activation. Selective activation of
dectin-1 significantly increases the magnitude of axonal injury
and tissue pathology compared with zymosan alone and dieback
of corticospinal tract (CST) axons is reduced in dectin-1 knock-
out (KO) mice. Conversely, selective TLR2 activation causes
florid inflammation but without causing marked neuropathol-
ogy. Importantly, it is possible to attenuate the injurious effects of
endogenous macrophages responding to SCI by injecting TLR2-
selective agonists into the injury site; augmenting TLR2 activation
reducesdieback (retraction)of injuredCNSaxonsandpromotes the
accumulation of axon growth-permissive molecules. Collectively,
these data implicate differentmacrophage PRRs in injury and repair
processes after CNS injury and identify new molecular targets for
achieving cell-specific immunemodulation.
Materials andMethods
Animals. Adult female Sprague Dawley rats (200–225 g; Harlan) or
C57BL/6 female Clec7a/ (dectin-1 KO) mice (provided by Dr. Gor-
don Brown at University of Cape Town, South Africa; Taylor et al., 2007)
and wild-type (WT) littermates were used for individual experiments.
Cells for in vitro analysis were prepared from adult C57BL/6 WT male
and female mice (8–12 weeks; Jackson Laboratory). All procedures were
performed in accordance with the guidelines and protocols of the Office
of Responsible Research Practices and with approval of the Institutional
Animal Care and Use Committees at The Ohio State University or the
University of Kentucky.
Spinal cord injuries. Rat dorsal column crush (DCC) injuries were
performed at C8 as previously described (Horn et al., 2008). Briefly, rats
were anesthetized with intraperitoneally injected ketamine (80 mg/kg)
and xylazine (50 mg/kg), and muscle and skin layers were dissected to
expose the gap between the T1 and T2 spinal processes. The ligament
between the spinal processes was removed to expose the C8 cervical
spinal level. Bilateral, pin-prick-size durotomies weremade withmicros-
cissors 0.75 mm lateral to midline to allow insertion of jeweler’s forceps
(Dumont #55) through the dura and into the arachnoidmater, piamater,
and then spinal cord to a depth of 1mm. Forceps were then retracted and
Dumont #3 jeweler forcepswere inserted into the spinal cord through the
same hole to a depth of 1 mm. Then a 1.5-mm-wide DCC lesion was
created by squeezing the forceps together three times, holding maximal
pressure for 10 s each time. For mice, a complete crush injury was per-
formed at the T9 spinal level. After performing a laminectomy, tips of a
Dumont #5 jeweler’s forceps were inserted bilaterally along the sides of
the exposed spinal cord until both tips touch the ventral surface of the
spinal canal. To cause injury, forceps were closed completely, held in
place for 2 s, and then released. Complete lesions were verified by obser-
vation of white-matter clearing (without damage to the dura).
Intraspinal macrophage activation. Rats were anesthetized with intra-
peritoneally injected ketamine (80mg/kg) and xylazine (50mg/kg) and a
T8/T9 laminectomywas performed as described previously (Popovich et
al., 2002; Gensel et al., 2009). For macrophage activation after DCC,
animals were anesthetized (as above) 2 d after injury and the injury site
re-exposed. Microinjections were performed via calibrated pressure mi-
croinjection (PV800 Pneumatic PicoPump, David Kopf Instruments)
using pulled glass micropipettes (PD-5 Micropipette Puller, Narishige).
Pipettes were beveled to an external diameter of 30–80 mm (Beveller
1300 M-C, World Precision Instruments) and were sterilized overnight
under UV light. To target the lateral white matter in the thoracic cord,
stereotaxic injections were made 900 mm lateral to midline and 800 mm
deep (Schonberg et al., 2007). For macrophage activation in the crush
site, stereotaxic injections were made on midline 500 mm deep into the
center of the injury.Macrophages were activated through 100 nl intraspi-
nal microinjections of zymosan (10 mg/ml; Sigma-Aldrich, catalog
#Z4250), depleted zymosan (10 mg/ml; InvivoGen, catalog #tlrl-dzn), 1
l microinjections of PAM2CSK4 (1 mg/ml; InvivoGen, catalog #tlrl-
pm2s), and PBS (vehicle) at a rate of 300 nl/min.
Axon labeling. Two days before killing rats via perfusion, while under
anesthetic, the dorsal column axons were labeled unilaterally with Texas
Red-conjugated 3000 molecular weight (MW) dextran (Invitrogen, cat-
alog #D-3328). The right sciatic nerve was exposed and crushed 3–3.5 cm
from the knee (4–5 mm from bifurcation of nerve) with Dumont #3
forceps for 10 s and repeated two additional times as described previously
(Horn et al., 2008; Ikeda et al., 2008). Via a 32-gauge Hamilton syringe,
1.5–2 l of 3000 MW dextran 10% in sterile water was injected into the
crush site. To traceCST axons inmice, 1l (total) of biotinylated dextran
amine (BDA; 10%) was injected into sensorimotor cortex at three sites
using a NanoJect system (anterior–posterior coordinates from bregma:
0.1, 2 mm; 1.5, 2 mm; and 1.5, 1.5 mm; all at a depth of 0.6 mm into
cortex). BDA injections were completed at 2 weeks postinjury, a time
when CST axons are undergoing axon dieback and activated macro-
phages are evident in the degenerating CST (Wang et al., 2009).
After SCI or intraspinal microinjection, muscle layers were sutured
with 4-0 nylon suture and the skin was closed with surgical staples. Post-
operatively, animals received 5 ml of subcutaneous saline, were kept
warm on a heating plate during recovery from anesthesia, and allowed
access to food and water ad libitum.
Tissue preparation, histology, and immunohistochemistry. At various
times after microinjection, dorsal column injury, or spinal cord crush
injury, animals were terminally anesthetized and transcardially perfused
with 0.1 PBS and then 4% paraformaldehyde. Spinal cords were re-
moved, postfixed for 2 h, and then rinsed in 0.2 M phosphate buffer and
stored overnight at 4°C. Tissueswere cryoprotected by immersing in 30%
sucrose over several days, then were blocked and embedded in Tissue-
Tek OCT (Fisher), and then frozen on dry ice. Frozen spinal cord blocks
were sectioned on a cryostat in either 10-m-thick frontal or 15–20-m-
thick longitudinal (from dorsal to ventral) sections. Tissues were labeled
using standard indirect immunofluorescence techniques. Primary anti-
bodies used were OX42 (1:2000; Serotec); Neurofilament-1 (NF-1;
1:1000; Aves); GFAP [1:20,000; Polysciences; or 1:2000; Wako (for
mouse immunohistochemistry)]; vimentin (1:500; Aves); Texas Red (1:
200; Life Technologies); ED-1 (1:1000; Serotec); -amyloid precursor
protein (APP; 1:1000; Invitrogen); tomato lectin (TomL; 1:1000; Sigma-
Aldrich); protein kinase C (PKC; 1:200; Santa Cruz Biotechnology);
NG2 (1:1000; United States Biological). Secondary Alexafluor (AF;
1:1000)-conjugated antibodies AF488, AF546, AF633 were used to visu-
alize primary antibody labeling. DAPI (Sigma-Aldrich) was used to label
cell nuclei. Sections were stained for macrophages/microglia (OX-42;
1:4000; mouse AbD Serotec) or axons (NF200; 1:5000; rabbit, Millipore
Bioscience Research Reagents) using peroxidase-based immunohisto-
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chemistry or eriochrome cyanine for myelin.
Images were captured using a Zeiss 510 Meta
(Carl Zeiss) confocal microscope, a Nikon
Eclipse Ti laser-scanning confocal microscope,
or an Axioplan 2 imaging (Carl Zeiss)
microscope.
Analysis. Sensory axon retraction from the
center of the DCC site (identified by the for-
ceps tracks and maximum width of gliosis),
CST retraction from the lesion edge (identified
by GFAP labeling), and rostral–caudal lesion
lengths were quantified using an Axioplan 2
imaging microscope (Zeiss) with a motorized
X-Y stage controlled by MCID image quantifi-
cation software (Imaging Research). As de-
scribed previously (Horn et al., 2008), the
distance of Texas Red-labeled axon retraction
was determined for three sections per animal
spaced 200 m apart and starting 200 m be-
low the dorsal surface of the spinal cord. As
performed previously, themeasurements from
all sections from all animals in a group were
averaged to determine the average distance of
retraction per time point (Horn et al., 2008). In
rat DCC injuries, lesion length was defined as
the widest area of pathology/gliosis per section
(Stirling et al., 2014). Retraction of dorsal CST
axons in mice was measured in one section per
mouse at a depth of280 m.
Lesion and macrophage volume estimates
were calculated using the Cavalieri method on
digitized images at 0.1 mm intervals centered
on the injection site (Donnelly et al., 2011).
Proportional areas of macrophage, NF, and vi-
mentin, were quantified similarly to tech-
niques used previously to quantify
macrophage activation (Donnelly et al., 2009;
Gensel et al., 2009). Briefly, the density of label-
ing above background was quantified using
threshold-based measures within predefined
areas on tissue sections. The MCID, Meta-
Morph (Molecular Devices), or ImageJ image
quantification software programs were used to
determine proportional area measurements.
For quantification of axon density within areas
of activated macrophages, manual counts of NF axons were normalized
to the area of activated, TomLmacrophages. Then the average of two
adjacent sections (100mapart) was used for each animal. For vimentin,
uniform areas were sampled from regions centered on BDA-labeled ax-
ons. TheMetaMorph colocalization plug-in was used to analyze colocal-
ization of vimentin with BDA-labeled axons.
Cell culture. Bone marrow-derived macrophages (BMDMs) were iso-
lated from the leg bones of C57BL/6mice as described previously (Long-
brake et al., 2007). Briefly, BMDMs were obtained from bilateral femurs
and tibias using aseptic techniques. Marrow cores were flushed into ster-
ile tubes using syringes fit with 26 gauge needles and filled with Roswell
Park Memorial Institute (RPMI) 1640 (or DMEM) plus 10% FBS. Cells
were triturated 3–5 and then red blood cells were lysed in lysis buffer
(0.15 M NH4Cl, 10 mM KHCO3, and 0.1 mM Na2EDTA, pH 7.4). Cells
were washed once in media, and then plated and cultured in differentia-
tion media: DMEM or RPMI 1640 supplemented with 1% penicillin/
streptomycin, 1% HEPES, 0.001% -mercaptoethanol, 10% FBS, and
20% supernatant from sL929 cells. The sL929 (which contains macro-
phage colony stimulating factor) is needed to promote differentiation of
bone marrow cells into macrophages with phenotypically similar prop-
erties as CNSmacrophages (7–10 d; Burgess et al., 1985; Longbrake et al.,
2007).
Macrophage-conditioned media (MCM) was generated as described
by Gensel et al. (2009). After 6 d in culture, BMDMs were cold-shocked
(eliminates need for trypsin) with media for 5 min and then removed
from flasks using a cell scraper (BD Falcon, catalog #353086). Cells were
replated overnight at 1  106 cells/ml in differentiation media without
sL929 supernatant. The following day, media was replaced with Neuro-
basal A (NBA)media supplementedwith 2%B27, 1%Glutamax, and 1%
penicillin-streptomycin containing zymosan (1.25mg/ml or 100g/ml),
PAM2CSK4 (200 ng/ml), depleted zymosan (1.25 mg/ml or 100g/ml),
or fresh NBA. Macrophages were activated for 8 h at 37°C in 5% CO2,
after which the MCMwas collected, centrifuged (1200 rpm, 5 min), and
then filtered (0.22 m low-protein binding filter; Millipore) to remove
the zymosan/stimulant particles and cell debris. All MCM was stored at
20°C.
Dorsal root ganglion (DRG) neurons were isolated from terminally
anesthetized adult WT C57BL/6 mice. DRG cultures were prepared on
glass coverslips as described previously (Gensel et al., 2009, 2010). Cell
death was determined by plating cells directly into MCM (1:1 MCM/
NBA-B27 base media) at 4000 cells/coverslip or plating at 400 cells/
coverslip and treating on the third day in vitro with MCM for 48 h. Five
days after plating, neurons were fixed with 2% paraformadehyde and
then labeled with -tubulin III (1:2000; Sigma-Aldrich) and AF546 and
DAPI (Sigma-Aldrich). The density of -tubulin III labeling was deter-
mined by randomly sampling digitized images of DRG cells. Numbers of
DRG neurons were estimated by unbiased counting of -tubulin III
neurons in randomized fields covering 45% of each coverslip (125
fields per coverslip; Gensel et al., 2009; Kigerl et al., 2009).
Figure 1. Intraspinal injections of dectin-1 (CLR) and TLR2 receptor agonists cause variable degrees of axonal injury and
demyelination. Cross-sections of rat thoracic spinal cord 3 d aftermicroinjecting TLR2 or dectin-1 (CLR) agonists. A–F, All agonists
activate macrophages (OX42, brown, A–C) but with varying degrees of myelin (eriochrome cyanine, blue, D–F ) and axon (NF,
brown, D–F ) pathology. G, Normalizing the area of axon/myelin pathology to area occupied by round OX42 macrophages
reveals marked differences in macrophage effector potential when activating these receptors, alone or in combination. A–G,
Pathology isminimalwhenTLR2 is activatedalone (PAM2CSK4, 1g in1.0l). Conversely, activatingCLR (D-ZYM,1g in0.1l)
causes significantly more pathology when compared with the effects of coactivating TLR2 and CLR (zymosan, 1 g in 0.1 l;
ANOVA p 0.0001; n 3 rats/group, macrophage and lesion volumes were quantified for each subject using the Cavalieri
method). H–M, Confocal projections reveal differences in axon preservation (H–J, NF) after activating TLR2 or CLR, alone and in
combination. Only when macrophages are activated via TLR2 alone (J, M ) do axons persist within the inflammatory foci (K–M,
right of thedotted line). In contrast, fewaxons remainwhenmacrophages are activated via dectin-1 (CLR), aloneor in combination
with TLR2 (H, I, K, L). The most significant pathology is evident after dectin-1 (CLR) activation; axon loss is evident beyond the
dense core of activatedmacrophages (I, L, left of dotted line).N, Quantification of axon density in areas colocalizedwith activated
macrophages reveals significant preservation of axons only when macrophages are activated by TLR2. Data are representative of
three independent experiments (n  3/rats/group/experiment). *p  0.05; ***p  0.001; ****p  0.0001 versus other
conditions. Scale bars: A–F, 50m; H–M, 20m.
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Statistical analysis.All datawere analyzedwith the investigator blind to
experimental conditions. All experimental data are representative of2
independent replicate experiments. Specific replicates and animal num-
bers are provided in the legends that accompany each dataset. Data were
analyzed usingANOVA followed byDunnett’s or Tukey’s test formultiple
comparisons. Independent-samples t tests were also used to compare two
groups separately. All p 0.05 were considered significant. Unless noted
otherwise, all data represent the mean  SEM. All analyses were per-
formed using Prism 5.0/6.0 (GraphPad Software). Figures were prepared
using Adobe Photoshop CS5/6 (Adobe Systems) and Prism 5.0/6.0.
Results
Selective activation of TLR2 or dectin-1 elicits distinct
macrophage functions in vivo and in vitro
Zymosan activates both TLR-2 and dectin-1 (CLR) receptors
found on microglia and macrophages. In brain and spinal cord,
ZAMs cause profound axonal injury, glial cell loss, and demyeli-
nation, but these cells also can enhance axon regeneration (Fitch
et al., 1999; Popovich et al., 2002; Yin et
al., 2003; Steinmetz et al., 2005; Okada et
al., 2006; Schonberg et al., 2007; Gensel et
al., 2009). To clarify the seemingly con-
flicting effects of coactivating macro-
phage TLR2 and CLRs, receptor-selective
agonists were injected into intact rat tho-
racic spinal cord. PAM2CSK4 is a TLR2-
selective agonist, whereas removing the
TLR2-stimulating component of zymo-
san allows selective activation of dectin-1.
Depleted zymosan (see Materials and
Methods) and heat-killed Saccharomyces
cerevisiae are both selective dectin-1 ago-
nists (Ikeda et al., 2008) and, when in-
jected into intact spinal cord, both CLR
agonists produced similar results. Ac-
cordingly, only depleted zymosan data are
described and are designated as “CLR” in
all figures.
To account for possible differences in
the magnitude of macrophage activation
caused by each agonist, lesion volumes
were normalized to macrophage volumes
(presented as the lesion/macrophage ra-
tio). Consistent with previous data from
our laboratory, coactivating TLR2 and
CLRs with zymosan caused axonal injury
and demyelination (Popovich et al., 2002;
Schonberg et al., 2007;Gensel et al., 2009).
Overall, 75% of the area occupied by
ZAMs was devoid of axons or myelin (Fig.
1A,D,G,H,K). However, ZAMs also were
colocalized with intact axons and myelin
(Fig. 1H,K). In contrast, activating only
dectin-1 caused a similarly robust macro-
phage reaction but all areas occupied by
macrophages were devoid of axons and
myelin and regions of pathology extended
beyond the inflammatory focus (ratio,
	1.0; Fig. 1B,E,G, I,L). Intraspinal injec-
tion of the TLR2 agonist PAM2CSK4, also
elicits a florid macrophage response but
with minimal axon or myelin pathology
(Fig. 1C,F,G, J,M).
In an independent experiment, axon
density was quantified within regions oc-
cupied by activated macrophages (Fig. 1H–N). Activating
dectin-1 alone increased axonal injury 	5-fold when compared
with selective activation of TLR2 (Fig. 1N). Coactivation of TLR2
and dectin-1 consistently caused pathology that was intermediate
between activation of TLR2 or dectin-1 alone (Fig. 1G,N). These
data indicate that TLR2 activation might mitigate the pathologic
effects of activating dectin-1.
Indeed, activation of TLR-2 resulted in the least amount of
axonal damage. Three-dimensional confocal reconstructions of
axons in the longitudinal plane confirmed the unique relation-
ship between TLR2-activated macrophages and spared (or
sprouting) axons. More intact axon profiles were found project-
ing through and around TLR2-activatedmacrophages thanmac-
rophages activated via dectin-1 (CLR) or dectin-1 plus TLR2 (Fig.
2A–F). Within foci of macrophages activated via both TLR2 and
dectin-1 or dectin-1 alone, either no neurofilament labeling was
Figure 2. Selective activation of macrophage dectin-1 (CLR), but not TLR2, causes axonal degeneration. Representative longi-
tudinal thoracic spinal cord sections 3 d aftermicroinjecting TLR2 and dectin-1 agonists. A–D, Axons in proximity tomacrophages
activated via CLR plus TLR2 (A, B, TLR2 CLR) or CLR (C, D) were not continuous and had dystrophic endings (arrows; note that
green “dots” in C andD are not fragmented axons; this is autofluorescence caused by depleted zymosan particles). E, F, In contrast,
intact axons coursed through areas occupied by TLR2-activated macrophages (arrows indicate continuous axon). G–L, Confocal
projections reveal accumulation of APP (purple) in injured axons. All agonists elicit comparable magnitudes of macrophage
activation (B,D,E, red); however, anotable increase inAPP staining is evident only after injectingadectin-1agonist (H,K, compare
with G, J and I, L). Scale bars: A–F, 3m; G–L, 100m.
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present or axonswere dystrophic or fragmented (Fig. 2A–D). The
autofluorescence caused by depleted zymosan particles (Fig. 2C)
obscures clear visualization of dystrophic axons in each condi-
tion. Accordingly, adjacent sections were immunolabeled to re-
veal -APP axon profiles. -APP is a sensitive measure of axon
injury (Pierce et al., 1996). More APP axons colocalized with
macrophages activated via dectin-1, either alone or in combina-
tion with TLR2 (Fig. 2G–L). Together, data in Figures 1 and 2
indicate that the neurotoxic effects of activated macrophages are
receptor dependent; activating dectin-1, a CLR, elicits patholog-
ical effector functions, whereas TLR2-activated macrophages do
not. Also, TLR2 activation may inhibit the pathologic effects of
activating dectin-1.
Since cells other than macrophages (and microglia) can
express TLRs (Kigerl and Popovich, 2009), we next tested
whether the in vivo effects of the dectin-1 and/or TLR2 ago-
nists were caused by direct activation of microglia/macro-
phages. Accordingly, in vitro assays were used. Specifically,
media conditioned by macrophages (MCM) activated with
zymosan (TLR2 plus CLR) or selective dectin-1 (CLR) or
TLR2 agonists were compared with media from unstimulated
macrophages. All MCM was overlaid onto cultured primary
adult DRG neurons.
When compared with MCM from unstimulated macro-
phages, which kills10–20% of neurons in culture, TLR2MCM
was neuroprotective. Greater numbers of DRG neurons were
present after exposure to TLR2 MCM and axons were protected
from spontaneous degeneration (Fig. 3A,B,E). Conversely, acti-
vating dectin-1 (CLR) caused significant neurotoxicity (Fig.
3A,B,D). Coactivating TLR2 with dectin-1 partially reversed the
neurotoxic effects of activating dectin-1 alone, but axon pathol-
ogy persisted (Fig. 3A–C).
Delayed delivery of a TLR2 agonist reprograms the injurious
effects of the endogenous macrophage response caused by SCI
Data in Figures 1–3 support the hypothesis that activating
dectin-1 causes macrophages to release neurotoxic factors while
TLR2 activation stimulates the release of neuroprotective or
growth-promoting factors. After SCI, macrophages actively pro-
mote axonal dieback (Popovich et al., 1999; Horn et al., 2008;
Evans et al., 2014). To test whether these injurious effects of the
endogenous macrophage response can be “reprogrammed,” a
TLR2-selective agonist, Pam2CSK4, was microinjected into
the injury site at 2 d postinjury (dpi), a time preceding the
onset of monocyte recruitment and macrophage-mediated
dieback (Horn et al., 2008). Two days before killing rats, a
subset of dorsal column sensory axons was labeled by injecting
fluorescent dextran into the sciatic nerve (Horn et al., 2008).
Two or 6 d after intraspinal injection of vehicle or Pam2CSK4
(corresponding with 4 or 8 dpi, respectively), spinal cords
were removed and the distances between ends of the labeled
fibers and the lesion center were quantified (Horn et al., 2008;
Busch et al., 2009).
Consistent with a previous report (Horn et al., 2008), sig-
nificant axonal dieback occurred 4–8 dpi in control SCI rats
with axons retracting 0.6 –0.8 mm during this time interval
(Fig. 4A,C,D,E). Conversely, in rats injected with a TLR2
agonist, axon dieback was reduced 40 and 15% at 4 and 8
dpi, respectively (Fig. 4B,C,F,G). Notably, within areas where
axon dieback was reduced, TLR2 activation enhanced the en-
dogenous macrophage response 	2-fold (Figs. 4D–G, 5).
Consistent with the observation that TLR2-activated macro-
phages attenuate axonal dieback, lesion size also was reduced
30% at 4 dpi (1.9  0.2 mm) versus vehicle (3.0  0.2 mm;
Fig. 5F ).
Published data indicate that vimentin-positive glial progeni-
tor cells provide a stabilizing substrate that protects dystrophic
axons from macrophage-mediated dieback (Busch et al., 2010;
Filous et al., 2014). To determine whether activating macro-
phages via TLR2 was associated with changes in this stabilizing
substrate, we examined vimentin immunoreactivity in proximity
to labeled axons. The density of vimentin labeling was signifi-
cantly increased after injecting the TLR2 agonist into the injured
spinal cord (1.5 vs vehicle; Fig. 6A–G). Also,more axonswere
closely apposed to vimentin-positive cells in the TLR2 condition
(Fig. 6H–N). Orthogonal confocal projections revealed that cells
positive for vimentin double-labeledwithNG2 (Fig. 6O–Q). Nei-
ther ED-1 macrophages (Fig. 6R–T) or GFAP astrocytes
(data not shown) colabeled with NG2. Since published data indi-
cate that vimentin in NG2 glial progenitor cells can protect
axons from dieback (Busch et al., 2010; Filous et al., 2014), these
data suggest that TLR2-activatedmacrophagesmay limit dieback
in part by creating an axon-stabilizing substrate at or near the
lesion.
Figure 3. Dectin-1 (CLR)-activated macrophages cause toxicity and axonal degeneration. MCM from macrophages activated via CLR plus TLR2 (TLR2CLR, zymosan) or CLR alone (depleted
zymosan) cause neurotoxicity and axonal degeneration, whereas MCM from TLR2-activated macrophages is neuroprotective or enhances axon growth. A, B, Total numbers of DRG neurons (A;
normalized to DRG neurons incubated with unstimulated MCM; ANOVA, p 0.0055; *p 0.05 vs other conditions) and overall density of-tubulin staining (B; ANOVA, p 0.0028, *p 0.01
vs CLR)were quantified as indices of neuron survival and axondegeneration, respectively. DRGneuronswere plated at lowdensity (400 cells per coverslip) and then, beginning onday 3 in vitro, were
stimulated with MCM for 2 d (A). C–F, Representative images of adult DRG neurons cultured for 5 d in the presence of different types of MCM (quantified in B). Data are representative of three
independent experiments. Dotted line in A and B represents unstimulated MCM. Scale bar, 50m.
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Dectin-1-mediated activation of macrophages contributes to
dieback of CST axons after SCI
To test the hypothesis that dectin-1 activation elicits destructive
effector functions in endogenous macrophages leading to axon
dieback, we analyzed the magnitude of CST retraction from the
injury site in dectin-1 KO or WT mice subjected to a complete
crush injury of the thoracic spinal cord (Taylor et al., 2007). CST
axondiebackwas significantly reduced in dectin-1KOmice com-
pared with WT littermate control mice (p  0.005; Fig. 7A–C).
Neither lesion size nor the magnitude of macrophage accumula-
tion was different between KO and WT animals (data not
shown). Complete injury to the dorsal CST was confirmed by
immunolabeling for PKC below the level of injury (Lieu et al.,
2013; Fig. 7D).
Discussion
Macrophages exert reparative and degradative effects on injured
tissue. Several variables likely contribute to this functional heter-
ogeneity, including the size/shape of the ligand, the polarization
state of responding macrophages, and the stochastic activation of
diverse macrophage receptors in both spared and lesioned tissue
(Gantner et al., 2005; Rosas et al., 2008; Goodridge et al., 2011;
Stirling et al., 2014). These variables have not been thoroughly stud-
ied in the context of traumatic SCI. In this report, we attempted to
define how two different families of macrophage PRRs—the TLRs
and CLRs—influence macrophage effector functions in the spinal
cord. Expression of each of these receptor families increases after
SCI, providing a molecular mechanism by which macrophages can
bind endogenous proteins and nucleic acids that are released or that
become newly synthesized by dead or damaged cells (Horn et al.,
2008; Chen et al., 2013; Kigerl et al., 2014). Data in this report show
that activating intraspinalmacrophages via the CLR dectin-1, either
in isolation or together with TLR2, causes pathology. Conversely,
TLR2-activated macrophages confer neuroprotection and are able
to attenuate pathology caused by dectin-1 activation.
Figure 4. TLR2-activated macrophages reduce axon dieback in vivo after SCI. A, B, Longitudinal spinal cord sections 4 d after DCC injury and 2 d after intraspinal injection of vehicle (A) or TLR2
agonist (Pam2CSK4; B). Dotted line indicates the center of the crush lesion. Inverted fluorescent images of BDA-labeled axons are presented below labeled sections in A and B. C, Significantly less
axon dieback (arrows) occurs when TLR2 agonist (Pam2CSK4) is microinjected comparedwith vehicle injections. *p 0.05, ***p 0.001 (n 3/group).D–G, High-powered confocal montages
of labeled axons in proximity to activated macrophages. Note the increase in macrophage (green, OX42) and axon (red, BDA-labeled) density closer to the lesion center (*) when lesion contains
TLR2-activatedmacrophages (F, G) compared with spinal cord injected with vehicle (D, E). Data are representative of two independent experiments (n 3/group in each experiment). Scale bars:
A, B, 500m; D–G, 212m.
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Figure5. Intraspinal injectionof TLR2 ligandelicits a floridmacrophage responseand reduces lesion size after SCI.A,B,D,E, Representative confocalmontagesof longitudinal spinal cord sections
4 d after DCC and 2 d after intraspinal injection (1l) of vehicle (A,B) or Pam2CSK4, a selective TLR2 agonist (D, E). Note themarked increase in the density ofmacrophages (green, OX42, quantified
in C) in or near the injury site in spinal cords injectedwith TLR2 agonist (E) versus vehicle (B). The rostral– caudal lesion length (lesion identified by dotted line) is significantly reduced in spinal cords
enriched with TLR2-activated macrophages (A vs D, quantified in F ). Images are representative of spinal cords obtained in two independent experiments. Individual animal data are presented in
Figure 4F (n 6–9 rats/group). **p 0.01. Scale bar, 200m.
Figure 6. TLR2-activatedmacrophages create amicroenvironment capable of stabilizing dystrophic axons after SCI. Confocal montages of longitudinal spinal cord sections 4 dpi. A–F, Vimentin
expression is increased 2 d after intraspinal injection (1l) of TLR2 agonist Pam2CSK4 (D–F ) compared with vehicle injection (A–C). Edge of the lesion center in A and D labeled with asterisks. G,
The density of vimentin labeling in proximity to labeled axons is significantly increased in spinal cords injected with the TLR2 agonist (**p 0.01, n 3/group). H–M, High-powered confocal
projections showmore axons closely associated with vimentin-positive cells (arrows) in spinal cords injected with TLR2 agonist. Arrowheads depict axons that are not associated with vimentin.N,
Significantly more axons were apposed to vimentin-positive cells following injection of the TLR2 agonist (***p 0.001, n 3/group). O–T, Confocal images reveal vimentin colocalization with
NG2-positive (O–Q) but not ED-1-positive (R–T ) cells (z-plane to the right and bottom of each image). Data are representative of two independent experiments. Scale bars: A–F, 100m; H–M,
50m; O–T, 10m.
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The unique functional properties associated with these differ-
ent PRRs endow macrophages with the ability to distinguish be-
tween bound/embedded stimuli and stimuli that are shed from
the samemicrobe or damaged/stressed cell. TLRs are activated by
low concentrations of soluble ligands, whereas CLRs are nonop-
sonic phagocytic receptors. CLRs sense carbohydrate moieties in
pathogens as well as glycosylated proteins and DAMPs derived
from apoptotic and necrotic cells (Gardai et al., 2006; Matsunaga
and Moody, 2009; Miyake et al., 2010; Donnelly et al., 2011). In
the injured CNS, this type of dual recognition scheme would
prioritize host defense at or near the injury site where entry of
microbes or other pathogens is likely, while allowingmacrophage
subpopulations in penumbra or spared tissues to respond to sol-
uble DAMPs that are newly expressed by injured neurons or glia.
Previously, our laboratory implicated TLR2 signaling in the
induction of a reparative macrophage phenotype after SCI. In-
deed, locomotor recovery is impaired and lesion pathology is
exacerbated in TLR2 KOmice (Kigerl et al., 2007; Donnelly et al.,
2009; Gensel et al., 2009). Independent reports showing that re-
generative axon growth or neuroprotection can be achieved by
injecting TLR2 agonists into the eye or an ex vivo SCI preparation
further supports a protective role for TLR2 signaling (Longbrake
et al., 2007; Hauk et al., 2010; Stirling et al., 2014). Data in the
present report show that delayed (2 dpi) intraspinal injection of a
TLR2 agonist enhances the endogenous macrophage response
without exacerbating lesion pathology. In fact, axon dieback and
secondary lesion expansion were significantly reduced. Associ-
ated with these changes was an increase in the number of
vimentin-positive NG2 glia. Previous data indicate that these
cells create a permissive or axon-stabilizing substrate that can
protect dystrophic axons from macrophage-mediated dieback
(Burgess et al., 1985; Longbrake et al., 2007; Busch et al., 2010).
Collectively, these data indicate that a broad therapeutic window
exists for manipulating macrophage effector functions and that
Figure 7. Genetic deletion of dectin-1 limits dieback of CST axons after SCI.A,B, Horizontal spinal cord sections revealing BDA-labeled dorsal CST axons (inverted) from individual dectin-1 KO (A)
or littermateWT controlmice (B) 5weeks after complete crush injury (3weeks after BDA labeling). Dotted line indicates the boundary of GFAP glial scar at a depth of280m(middle of dorsal
CST) from the dorsal surface of the spinal cord. C, Quantification of distance of BDA-labeled CST fibers from the lesion border reveals that CST axon dieback is significantly reduced in dectin-1 KOmice
(vs WT controls). D, Cross-sections of mouse spinal cord caudal to the injury stained with anti-PKC antibody. Normal (intact) CST axons are PKC. Absence of PKC labeling confirms complete
injury to dorsal CST axons (dotted line) after SCI. **p 0.003 (n 7 dectin-1 KO mice; n 5WTmice). Scale bar, 200m. Data are the combined results of two independent experiments.
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TLR2 may be a novel target for therapeutic development. Also,
the in vivo neuroprotective effects of delayed macrophage activa-
tion via TLR2 may be as effective or more effective than systemic
macrophage depletion (Popovich et al., 1999; Horn et al., 2008;
Gensel et al., 2009). Other TLRs, including TLR4 and TLR3, also
may be therapeutic targets after SCI (Gensel et al., 2009, 2010;
Kigerl and Popovich, 2009). Systemic injections of LPS, a TLR4
agonist, augment intraspinal macrophage recruitment while re-
ducing tissue damage and increasing axonal growth/sprouting
after SCI. These neuroprotective effects were associated with
modest improvements in functional recovery (Guth et al., 1994;
Gensel et al., 2009; Popovich et al., 2012). TLR3 ligands can
increase production of neurotrophic factors and anti-
inflammatory cytokines (Kigerl et al., 2009; Bsibsi et al., 2012);
however, these effects may not bemacrophage specific and direct
injection of TLR ligands can adversely affect axon growth and
plasticity (Popovich et al., 2002; Cameron et al., 2007; Schonberg
et al., 2007; Gensel et al., 2009, 2012).
In contrast to the effects of activating TLR2, no benefit was
associated with intraspinal activation of dectin-1. When injected
into intact spinal cord, dectin-1 agonists caused axon loss and
demyelination, whereas axon dieback was reduced in mice defi-
cient in dectin-1. Like TLRs, dectin-1 signaling activates both
nuclear factor B and MAPK cascades; however, dectin-1 also
may impart unique and presumably pathological effector func-
tions (e.g., respiratory burst, phagocytosis) in macrophages
through the immunoreceptor tyrosine-based activation motif in
its cytoplasmic domain that recruits the tyrosine kinase Syk (Yin
et al., 2003; Okada et al., 2005; Steinmetz et al., 2005; Brown,
2006; Gensel et al., 2009).
Although unique functional attributes are associated with ac-
tivating TLR2 or dectin-1 in the intact spinal cord, after SCI these
receptors are coexpressed by macrophages and it is likely that
simultaneous activation of these receptors occurs in the dynamic
lesion microenvironment. How intraspinal macrophages re-
spond to zymosan is instructive in this context since zymosan
activates both TLR2 and dectin-1. Published data indicate that,
like macrophages that become activated by SCI, zymosan-
activated macrophages can kill neurons but they also create a
microenvironment that supports axon regeneration (Popovich et
al., 2002; Yin et al., 2006; Schonberg et al., 2007; Gensel et al.,
2009). Our current data indicate that the effects of CLR ligation,
alone or in synergy with TLR2, predominate at the injury site and
the net effect of engaging both TLRs and nonopsonic CLRs does
more harm than good. Indeed, when injected into injured spinal
cord, zymosan failed to induce axon growth or neuroprotection
(McPhail et al., 2004; Ward et al., 2014). Also, Kroner et al.
showed that synergistic signaling induced by phagocytosis and
cytokines released downstream of TLR activation potentiate the
development of a destructive inflammatory macrophage pheno-
type (Kigerl and Popovich, 2009; Kroner et al., 2014). Those au-
thors also found that the default pathway for macrophage
polarization after SCI is not necessarily destructive. Myelin
phagocytosis, which is prominent in the lesion early after SCI, can
trigger anti-inflammatory or resolution signaling in macro-
phages. However, the signaling required for induction of an anti-
inflammatory macrophage phenotype is subjugated by other
signaling cascades initiated by iron phagocytosis and inflamma-
tory cytokines (e.g., TNFa; Kroner et al., 2014). These latter sig-
nals predominate in the lesion core and likely squelch signaling
induced by myelin. Even if iron-dependent and TNF-dependent
signaling were reduced, the possibility remains that impaired
phagocytosis of myelin (“frustrated phagocytosis”) would con-
tinue to fuel destructive inflammation via overactivation of
dectin-1 or other CLRs (Rosas et al., 2008). Our current data
indicate that blocking CLRs or augmenting specific TLR signal-
ing pathways could be a novel way to reduce inflammatory
macrophage-mediated injury after SCI.
Even when the same receptor is activated on different cells,
ligand dimorphism and the magnitude of receptor cross-linking
could promote polarization of distinct macrophage phenotypes.
As an example, solubilized -glucans do not effectively activate
dectin-1, whereas particulate/bound-glucans form “phagocytic
synapses” that fully activate dectin-1 signaling pathways (Goo-
dridge et al., 2011). A practical application of this divergent rec-
ognition by dectin-1 was described for fungal (yeast) infections.
Reproductive budding in yeast leaves scars where -glucans are
exposed. This form of bound -glucan is a potent dectin-1 ago-
nist. Conversely, in its filamentous form, Candida albicans does
not activate dectin-1 because -glucans are not accessible (Gant-
ner et al., 2005). An analogy in the injured spinal cord might be
structural or intracellular chaperone proteins that are normally
sequestered in intact cells but then are exposed as cells become
stressed or die. If bound to dying cells or released and sequestered
in the surrounding extracellular matrix, these ligands could pref-
erentially activate dectin-1 or other CLRs. Other soluble DAMPs
could diffuse throughout the lesion and spared tissue and activate
macrophages via TLRs without concurrent CLR ligation. In this
context, recent data show that dissolving chondroitin sulfate
proteoglycan-enriched glial scars, a reaction that likely solubilizes
various PRR ligands, elicits a reparative macrophage phenotype
(Bartus et al., 2014; Didangelos et al., 2014).
While the present data are an oversimplification of the com-
plex and stochastic nature by which macrophages become acti-
vated after SCI, they highlight the need for future studies that
consider how the lesion microenvironment affects the expres-
sion of other macrophage receptors. In addition to TLRs and
CLRs, macrophages express scavenger receptors, integrins,
chemokine and cytokine receptors, and various cytosolic pro-
teins [e.g., nucleotide-binding oligomerization domains (NODs)
andNAcht leucine-rich-repeat proteins (NALPs)] capable of reg-
ulating intracellular signaling that will ultimately determinemac-
rophage phenotype (Taylor et al., 2005).
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